Daniel J. Freeman

5.4k total citations · 2 hit papers
40 papers, 3.9k citations indexed

About

Daniel J. Freeman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Daniel J. Freeman has authored 40 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Daniel J. Freeman's work include Colorectal Cancer Treatments and Studies (17 papers), HER2/EGFR in Cancer Research (13 papers) and Lung Cancer Treatments and Mutations (11 papers). Daniel J. Freeman is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), HER2/EGFR in Cancer Research (13 papers) and Lung Cancer Treatments and Mutations (11 papers). Daniel J. Freeman collaborates with scholars based in United States, Italy and Japan. Daniel J. Freeman's co-authors include Robert Radinsky, Todd Juan, Rafael G. Amado, Michael Wolf, Sid Suggs, Scott D. Patterson, Eric Van Cutsem, Marc Peeters, Salvatore Siena and David Chang and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Nature Reviews Drug Discovery.

In The Last Decade

Daniel J. Freeman

38 papers receiving 3.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

2008 2.4k citations Rafael G. Amado, Michael Wolf et al. Journal of Clinical Oncology profile →
Optimizing oncolytic virotherapy in cancer treatment

2019 384 citations Kevin J. Harrington, Daniel J. Freeman et al. Nature Reviews Drug Discovery profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Daniel J. Freeman	2.8k	1.3k	1.0k	980	768	40	3.9k
Delphine Le Corre	3.0k 1.1×	1.3k 1.0×	1.3k 1.3×	1.3k 1.3×	1.3k 1.7×	33	4.7k
Eric A. Collisson	2.9k 1.0×	2.2k 1.7×	1.0k 1.0×	662 0.7×	2.1k 2.7×	81	5.2k
W. Michael Korn	2.1k 0.7×	1.2k 0.9×	769 0.8×	654 0.7×	906 1.2×	197	3.4k
Barrett H. Childs	2.1k 0.8×	572 0.4×	585 0.6×	731 0.7×	567 0.7×	101	3.3k
Hideaki Bando	2.0k 0.7×	1.3k 1.0×	1.1k 1.0×	668 0.7×	799 1.0×	205	3.6k
Salvatore Piscuoglio	1.7k 0.6×	2.5k 1.9×	1.0k 1.0×	861 0.9×	2.7k 3.5×	133	5.3k
David S. Rickman	1.4k 0.5×	2.8k 2.2×	1.6k 1.6×	855 0.9×	1.6k 2.1×	63	5.6k
Víctor Moreno	3.8k 1.3×	1.8k 1.4×	1.2k 1.2×	520 0.5×	624 0.8×	287	5.5k
Hendrik‐Tobias Arkenau	2.3k 0.8×	1.5k 1.2×	1.2k 1.2×	557 0.6×	769 1.0×	214	4.1k
Charlotte K.Y. Ng	2.6k 0.9×	2.4k 1.8×	1.5k 1.4×	1.4k 1.4×	3.5k 4.5×	120	6.5k

Countries citing papers authored by Daniel J. Freeman

Since Specialization

Citations

This map shows the geographic impact of Daniel J. Freeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Freeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Freeman more than expected).

Fields of papers citing papers by Daniel J. Freeman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel J. Freeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Freeman. The network helps show where Daniel J. Freeman may publish in the future.

Co-authorship network of co-authors of Daniel J. Freeman

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel J. Freeman. A scholar is included among the top collaborators of Daniel J. Freeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel J. Freeman. Daniel J. Freeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Freeman, Daniel J., Catherine Diefenbach, Linda Lam, et al.. (2024). terraFlow, a high-parameter analysis tool, reveals T cell exhaustion and dysfunctional cytokine production in classical Hodgkin’s lymphoma. Cell Reports. 43(8). 114605–114605. 3 indexed citations

Gopalakrishnan, Vancheswaran, Bryan J. Weiner, Christopher B. Ford, et al.. (2020). Intervention strategies for microbial therapeutics in cancer immunotherapy. Immuno-Oncology Technology. 6. 9–17. 11 indexed citations

Harrington, Kevin J., Daniel J. Freeman, Elizabeth J. Kelly, James A. Harper, & Jean‐Charles Soria. (2019). Optimizing oncolytic virotherapy in cancer treatment. Nature Reviews Drug Discovery. 18(9). 689–706. 384 indexed citations breakdown →

Mendell, Jeanne, Daniel J. Freeman, Wenqin Feng, et al.. (2015). Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer. EBioMedicine. 2(3). 264–271. 30 indexed citations

Boedigheimer, Michael, et al.. (2013). Gene Expression Profiles Can Predict Panitumumab Monotherapy Responsiveness in Human Tumor Xenograft Models. Neoplasia. 15(2). 125–132. 5 indexed citations

Crawford, Jeffrey, Paul Swanson, Paul Schwarzenberger, et al.. (2013). A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(12). 1510–1518. 18 indexed citations

Freeman, Daniel J., Kevin S. McDorman, Carl J. Kozlosky, et al.. (2012). Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Molecular Cancer. 11(1). 47–47. 24 indexed citations

Wurz, Ryan P., Longbin Liu, Kevin Yang, et al.. (2012). Synthesis and structure–activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold. Bioorganic & Medicinal Chemistry Letters. 22(17). 5714–5720. 23 indexed citations

Zhang, Nancy R., Sean Caenepeel, Ling Wang, et al.. (2012). Abstract 2797: AMG 511, a potent and selective class I PI3K inhibitor, demonstrates anti-tumor activity in multiple xenograft models. Cancer Research. 72(8_Supplement). 2797–2797. 1 indexed citations

10.

Martić, Sanela, Mahmoud Labib, Daniel J. Freeman, & Heinz‐Bernhard Kraatz. (2011). Probing the Role of the Linker in Ferrocene–ATP Conjugates: Monitoring Protein Kinase Catalyzed Phosphorylations Electrochemically. Chemistry - A European Journal. 17(24). 6744–6752. 34 indexed citations

11.

Oliner, Kelly S., Todd Juan, Sid Suggs, et al.. (2010). A comparability study of 5 commercial KRAS tests. Diagnostic Pathology. 5(1). 23–23. 44 indexed citations

12.

Zeng, Qingping, Matthew P. Bourbeau, Holger Monenschein, et al.. (2010). 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics. Bioorganic & Medicinal Chemistry Letters. 20(5). 1652–1656. 15 indexed citations

13.

Amado, Rafael G., Michael Wolf, Marc Peeters, et al.. (2008). Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 26(10). 1626–1634. 2400 indexed citations breakdown →

14.

Freeman, Daniel J., et al.. (2008). Fully human Anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors. Cancer Research. 68. 19 indexed citations

15.

Freeman, Daniel J., Todd Juan, Maureen Reiner, et al.. (2008). Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone. Clinical Colorectal Cancer. 7(3). 184–190. 129 indexed citations

16.

Kruser, Tim J., Eric A. Armstrong, Amol J. Ghia, et al.. (2008). Augmentation of Radiation Response by Panitumumab in Models of Upper Aerodigestive Tract Cancer. International Journal of Radiation Oncology*Biology*Physics. 72(2). 534–542. 34 indexed citations

17.

Amado, Rafael G., Michael Wolf, Daniel J. Freeman, et al.. (2007). 7LB Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy. European Journal of Cancer Supplements. 5(6). 8–8. 17 indexed citations

18.

Chang, Chun-Ju, Daniel J. Freeman, & Hong Wu. (2004). PTEN Regulates Mdm2 Expression through the P1 Promoter. Journal of Biological Chemistry. 279(28). 29841–29848. 81 indexed citations

19.

Freeman, Daniel J., Gang Wei, Nathalie Kertesz, et al.. (2003). PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 3(2). 117–130. 403 indexed citations

20.

Freeman, Daniel J. & Ralph W. Niven. (1996). The Influence of Sodium Glycocholate and Other Additives on the in vivo Transfection of Plasmid DNA in the Lungs. Pharmaceutical Research. 13(2). 202–209. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact